The Law Office of Robbins Umeda LLP
Announces an Investigation of the Acquisition of
Genoptix, Inc. by Novartis AG
January 24, 2011 02:31 PM Eastern Time
SAN DIEGO--(EON: Enhanced Online News)--Robbins Umeda LLP has commenced an investigation into
possible breaches of fiduciary duty and other violations of state law by members of the board of directors of
Genoptix, Inc. (NASDAQ:GXDX) in connection with their efforts to sell the company to Novartis AG
(NYSE:NVS). If the transaction is completed, Genoptix shareholders will receive $25.00 in cash for each share of
Genoptix common stock they hold. The transaction is expected to close in the first half of 2011.
Robbins Umeda LLP's investigation concerns whether the Genoptix board undertook a fair process to obtain fair
consideration for its shareholders. Specifically, the investigation concerns whether members of the Genoptix board
breached their fiduciary duties to its shareholders by failing to adequately shop the company before entering into the
transaction with Novartis.
If you are a shareholder of Genoptix, plan to continue to hold your shares, and would like more information about
your rights as a shareholder, please contact attorney Gregory E. Del Gaizo at 800-350-6003 or by e-mail at
Robbins Umeda LLP represents individual and institutional shareholders in derivative, direct, and class action
lawsuits. The law firm's skilled litigation teams include former federal prosecutors, former defense counsel from top
multinational corporate law firms, and career shareholder rights lawyers. Robbins Umeda LLP has helped its clients
realize more than $1 billion of value for themselves and the companies in which they have invested. For more
information, please go to http://www.robbinsumeda.com.
Attorney Advertising. Past results do not guarantee a similar outcome. We invite you to contact us today to discuss
Robbins Umeda LLP
Gregory E. Del Gaizo, 800-350-6003